The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
The role of non-resolving inflammation in atherosclerosis
Open accessAbstract
Non-resolving inflammation drives the development of clinically dangerous atherosclerotic lesions by promoting sustained plaque inflammation, large necrotic cores, thin fibrous caps, and thrombosis. Resolution of inflammation is not merely a passive return to homeostasis, but rather an active process mediated by specific molecules, including fatty acid-derived specialized pro-resolving mediators (SPMs). In advanced atherosclerosis, there is an imbalance between levels of SPMs and proinflammatory lipid mediators, which results in sustained leukocyte influx into lesions, inflammatory macrophage polarization, and impaired efferocytosis. In animal models of advanced atherosclerosis, restoration of SPMs limits plaque progression by suppressing inflammation, enhancing efferocytosis, and promoting an increase in collagen cap thickness. This Review discusses the roles of non-resolving inflammation in atherosclerosis and highlights the unique therapeutic potential of SPMs in blocking the progression of clinically dangerous plaques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both SPMs and IL-10 promote efferocytosis36,93,181–185”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chistiakov, D. A., Bobryshev, Y. V., Nikiforov, N. G., Elizova, N. V., Sobenin, I. A., & Orekhov, A. N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.055 · Cited by 184
RetractedAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,880
Cytokine-mediated regulation of CXCR4 expression in human neutrophils
Nagase, H., Miyamasu, M., Yamaguchi, M., Imanishi, M., Tsuno, N. H., Matsushima, K., Yamamoto, K., Morita, Y., & Hirai, K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.711 · Cited by 4,713
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Self-citationMechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,389
Flagged first, then by citations
1 of the 135 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1161/CIRCULATIONAHA.117 · DOI
Cited by
Sorted by citations
Items 201–266 of 266
Place of lipid theory in history of study of atherosclerosis
Kotlyarov, S. N. (2024) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj636812 · Cited by 5
Wang, W., Xu, D., Ding, J., Zhang, W., Fan, J., & Wang, D. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3597 · Cited by 4
Moissl, A. P., Delgado, G. E., Kleber, M. E., Mooren, F. C., Schäfer, H., Krämer, B. K., März, W., & Schmitz, B. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf154 · Cited by 4
Colchicine for Secondary Cardiovascular Prevention: A Systematic Review
Webb, C. A., & Barry, A. R. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2401 · Cited by 4
Effect of a new squalene synthase inhibitor on an ApoE−/− mouse model of atherosclerosis
Matralis, A. N., Kaklamanis, L., Perrea, D. N., & Kourounakis, A. P. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117378 · Cited by 4
LncRNA SCARNA8 promotes atherosclerotic plaque instability by inhibiting macrophage efferocytosis
Yin, X., Chen, X., Wang, T., Yang, J., Yu, J., & Yang, J. (2025) · Epigenetics · doi:10.1080/15592294.2025.2487317 · Cited by 3
Identification of Myeloid Protein Kinase C Epsilon as a Novel Atheroprotective Gene
Wells, A. T., Ramos, R. B., Shen, M. M., Binrouf, R. H., Swinegar, A. E., & Lennartz, M. R. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.323005 · Cited by 3
Good, E., Ochoa-Figueroa, M. A., Ziegler, M., Ressner, M., Warntjes, M. J. B., Dyverfeldt, P., Lubberink, M., Ahlström, H. K., & de Muinck, E. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-93605-x · Cited by 3
A bibliometric analysis of efferocytosis in cardiovascular diseases from 2001 to 2022
Hu, L., Lv, Z., Gu, Y., Zheng, T., Kong, Y., & Mao, W. (2023) · Medicine · doi:10.1097/md.0000000000034366 · Cited by 3
Prophylactic stenting of vulnerable plaques: pros and cons
Park, D., Kim, H., Singh, A., & Brown, D. (2024) · EuroIntervention · doi:10.4244/eij-e-24-00004 · Cited by 3
Kagaya, H., Kim, A. S., Chen, M., Lin, P., Yin, X., Spite, M. R., & Conte, M. S. (2024) · Physiological Reports · doi:10.14814/phy2.16178 · Cited by 3
Wang, H., Zhang, P., Chen, X., Liú, W., Fu, Z., & Liu, M. (2021) · Steroids · doi:10.1016/j.steroids.2021.108887 · Cited by 3
Land, W. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53868-2_10 · Cited by 3
Mayer, F., & Binder, C. J. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-12270-6_10 · Cited by 3
Prospects of black phosphorus nanosheets in the treatment of peri-implantitis
Wu, A., Su, J. F., Zhang, Y., Zhang, D., & Chen, Y. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adb66e · Cited by 2
Network Medicine-Based Repurposing of Mesalazine for Atherosclerosis Treatment
Jiang, J., Zheng, Z., Jiang, C., Wu, T., Shi, W., Liu, M., Fan, Q., & Cui, G. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10637-8 · Cited by 2
Влияние адипонектина на продукцию аполипопротеинов А-1 и Е макрофагами человека
Танянский, Д. А., Сергеевич, Т. А., Агеева, Е. В., Никитин, А. А., Shavva, V. S., & Orlov, S. (2021) · Molecular Biology · doi:10.31857/s0026898421040121 · Cited by 2
Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: what is next?
Arnold, N., & Köenig, W. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000909 · Cited by 2
Tempe Kedelai (Rhizopus oligosporus) sebagai Alternatif Anti Inflamasi
Husna, A., Emriadi, E., & Ristiono, B. (2021) · Andalas Dental Journal · doi:10.25077/adj.v9i2.183 · Cited by 2
The Influence of Adiponectin on Production of Apolipoproteins A-1 and E by Human Macrophages
Tanyanskiy, D. A., Trulioff, A. S., Владимировна, А. Е., Nikitin, A. A., Shavva, V. S., & Orlov, S. (2021) · Molecular Biology · doi:10.1134/s0026893321030122 · Cited by 1
Mayer, F., Innerhofer, R., Köller, T., & Binder, C. J. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_10 · Cited by 1
Targeting inflammation in atherosclerosis: prospects and limitations
Tanyanskiy, D. A., Denisenko, A. D., & Pigarevsky, P. V. (2025) · Cytokines and inflammation · doi:10.17816/ci699662 · Cited by 1
Zheng, L., Zhang, Q., Lian, H., Wang, W., Li, L., Zhen, Z., Li, Z., Zhao, L., Zhang, T., Zheng, B., et al. (2024) · Nanotechnology Reviews · doi:10.1515/ntrev-2024-0022 · Cited by 1
Liu, T., Fan, S., Li, J., Wang, T., Zhang, J., & Wang, C. (2026) · Microbiome · doi:10.1186/s40168-026-02396-8 · Cited by 1
Zhang, S., Yu, Y., 楼海亚, Zheng, X., Song, G., Wang, Z., Wang, K., Yuan, H., & HU, F. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114958 · Cited by 1
Peripheral Arterial Atherogenesis
Meyer, J., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2022) · Contemporary cardiology · doi:10.1007/978-3-031-09741-6_1 · Cited by 1
Cave, L., Lodge, K. M., Chiappo, D., Sinha, S., Chughtai, F., Tsao, A., Haskard, D. O., Mason, J. C., Humphries, S. E., & Boyle, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119623 · Cited by 1
Oxidative Stress, Atherosclerosis and Dietary Recommendations
DEMİRBAŞ, A. B., & Yeşilkaya, B. Y. (2021) · Akdeniz Medical Journal · doi:10.53394/akd.1037799 · Cited by 1
Resolution to Inflammation: Its Role in Reducing Fibrosis and Tissue Repair
Meiliana, A., & Wijaya, A. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i2.2181 · Cited by 1
Ayan, D., Sivri, A. B. Ç., Yüksel, S., Yetkin, İ., & Özdemi̇r, H. (2018) · Journal of Surgery and Medicine · doi:10.28982/josam.440016
Inflammation and Atherosclerotic Cardiovascular Disease
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_14
Fang, S., Sun, S., Cai, H., Hao, X., Zou, X., Wan, X., Tian, J., Li, Z., Wang, S., He, Z., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.06.425662
Mendes, A. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-08042021-081746
ApoE-Knockout Mice: What are New Achievements of this Model of Atherosclerosis?
Lorkowska-Zawicka, B., & Jawień, J. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0737
Risk factors and pharmacological therapy in patients with vascular disease
Maiolino, G., Rossato, M., & Vettor, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822113-6.00021-8
Macrophages in cardiovascular diseases
Zhang, H., Ben, J., XuDong, Z. H. U., & Chen, Q. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0245
Nogueira, M. S. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2020.tde-20122021-112905
Colestar: programa de cómputo interactivo de la regulación del colesterol sanguíneo en humano
Márquez, J. J. P., Pérez, J. Q., Monreal, M. R., Escalera, M. F. P., Lazalde, A. R., & Bonilla, M. E. P. (2022) · South Florida Journal of Development · doi:10.46932/sfjdv3n4-091
Leão, M. D. C. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2022.tde-30112022-111709
Good, E. (2022) · Linköping University medical dissertations · doi:10.3384/9789179295660
Alsina‐Sanchís, E., Mülfarth, R. I., Moll, I., Mogler, C., Rodríguez‐Vita, J., & Fischer, A. (2023) · doi:10.1158/1541-7786.c.6545141.v1
Coronel, L., Miguel, M. I., Blasi, J., Marsal, S., D’Agostino, M. A., & Möller, I. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2023-eular.3169
Jiang, H. X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4874369
Zhang, T., Yuan, C., Chen, M., Liu, J., Shao, W., & Cheng, N. (2025) · European journal of medical research · doi:10.1186/s40001-025-02940-6
Kim, S. H., Lee, S.-H., Kim, H.-R., & Min, H. K. (2021) · Figshare · doi:10.6084/m9.figshare.16531435
Miao, Y., Yan, T., Liu, J., Zhang, C., Yan, J., Xu, L., Zhang, N., & Zhang, X. (2024) · Figshare · doi:10.6084/m9.figshare.25834118
Cardosa, S. R., Ogunkolade, B.-W., Lowe, R., Savage, E., Mein, C. A., Boucher, B. J., & Hitman, G. A. (2021) · Figshare · doi:10.6084/m9.figshare.15178869
Cardosa, S. R., Ogunkolade, B.-W., Lowe, R., Savage, E., Mein, C. A., Boucher, B. J., & Hitman, G. A. (2021) · Figshare · doi:10.6084/m9.figshare.15178866
Cardosa, S. R., Ogunkolade, B.-W., Lowe, R., Savage, E., Mein, C. A., Boucher, B. J., & Hitman, G. A. (2021) · Figshare · doi:10.6084/m9.figshare.15178863
Wu, X.-B., Liu, Y.-A., Huang, L.-X., Guo, X., Cai, W.-Q., Luo, B., & Wang, S.-W. (2023) · Figshare · doi:10.6084/m9.figshare.24202624
Cardosa, S. R., Ogunkolade, B.-W., Lowe, R., Savage, E., Mein, C. A., Boucher, B. J., & Hitman, G. A. (2021) · Figshare · doi:10.6084/m9.figshare.15178872
Cardosa, S. R., Ogunkolade, B.-W., Lowe, R., Savage, E., Mein, C. A., Boucher, B. J., & Hitman, G. A. (2021) · Figshare · doi:10.6084/m9.figshare.15178875
Tian, J., Wang, S., Chang, X., & Han, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1746512 · Cited by 1
Role of Wnt5a in lysosoma l function : intracellular cholesterol accumulation and atherosclerosis
Awan, S. (2019) · theses.fr (ABES) · doi:10.70675/c7de7e4azdc16z4d22zbf82z586da191a349
Study of Interferon type I in Myasthenia Gravis
Payet, C. A. (2021) · theses.fr (ABES) · doi:10.70675/2cf393aez8d32z4cb0zb8adza6d9cf212520
Resolvin D2 attenuates platelet activation and thrombosis via the GPR18 receptor
Ji, Y., Wang, M., Sun, P., Zhao, Q., & Cai, S. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153805
Bae, J. S., Yi, H. J., & Shin, D.-S. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.112051
How Advanced is Nanomedicine to Treat Atherosclerosis? A Comprehensive Review of the Literature
Zhang, J., Tong, J., Sun, Y., Sun, J., Gao, R., Sun, D., Guo, X., & Wei, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s563561
Loss of IGFBP-6 promotes monocyte-driven atherogenesis in periodontal disease
Shanahan, D., Kremastiotis, G., Wadey, K. S., Hodgson, C. M., Seong, J. D., West, N., Nobbs, A. H., Johnson, J., & George, S. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-47023-6
Duan, Y., Qiu, Y., Zhu, Y., Wang, Q., Lin, J., Duan, Y., Wang, Q., & Dong, Y. (2026) · Advanced Science · doi:10.1002/advs.77100
Gu, M., Qiu, Y., Wang, Y., Xu, J., Liao, Z., Li, R., & Wu, W. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117327
Gao, Y., Bai, Y., Zeng, J., Wang, Y., Zhang, Y., Jia, M., Guo, Y., Qiu, J., Li, Y., Fu, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10939219/v1
Lan, M., Zhou, Y., Sun, Y., Yi, X., Long, M., Hermann, D. M., Fengyan, J., & Dai, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1957621
Natural products targeting efferocytosis: Bioactivities and therapeutic potential
Zhang, G., Geng, B., Zhang, S., & Xu, J. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-51068-7.00016-7
Krasiński, Z., Raffa, G. M., Kowalewski, M., Krasińska, B., Pisano, C., Cannata, S., Suwalski, P., & Urbanowicz, T. K. (2026) · Cells · doi:10.3390/cells15211995
Metadata
- Authors
- Kasikara, C., Doran, A. C., Cai, B., & Tabas, I.
- Affiliations
- Columbia University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-02
- Volume
- 128
- Issue
- 7
- Pages
- 2713-2723
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6025992
- OpenAlex
- W2809703637
- Cited by
- 266
- References
- 135
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 28 · 2023: 37 · 2022: 43 · 2021: 46 · 2020: 39 · 2019: 25 · 2018: 7
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association (17FTF33660643, 15POST25620024)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL132412, R01HL127464, P01HL087123, R01HL075662, T32HL120826)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- nonresolving inflammation, atherosclerosis, specialized pro-resolving mediators, inflammation resolution, atherosclerotic plaque, necrotic core, fibrous cap, thrombosis, macrophage polarization, efferocytosis, leukocyte influx, lipid mediators, plaque progression
- MeSH terms
- Animals, Humans, Inflammation, Models, Cardiovascular, Signal Transduction, Disease Progression, Inflammation Mediators, Atherosclerosis, Lipid Metabolism, Plaque, Atherosclerotic, Lipoxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review